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It has long been believed that the tumor suppressor promyelocytic leukemia (PML), the
core component of the nuclear substructures known as the PML-nuclear bodies, plays a key
part in acute PML (APL), as it is first cloned at the breakpoint of the t(15;17) translocation
typical of that disease. Research over the past decade, however, has radically changed our
view of how this tumor suppressor is regulated, how it can be therapeutically targeted, and
how it functions in a number of tissue systems. One noteworthy recent study, for instance,
revealed that PML regulates the activation of fatty acid metabolism, and that this metabolic
reprograming plays an essential role in cancer biology and stem cell biology through the
control it exerts over stem cell fate decisions.These findings sparked exciting new investi-
gations of PML as a critical “rheostat” responsible for fine-tuning tissue homeostasis, and
thus created at the intersection of cancer and stem cell biology a new field of study with
important therapeutic implications.
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MULTI-FUNCTIONAL PROTEIN, PML
The tumor suppressor promyelocytic leukemia (PML) was first
identified as a fusion partner of human retinoic acid receptor
alpha (RARα) as the result of a chromosomal translocation dis-
covered in acute PML (APL) (de The et al., 1991; Kakizuka et al.,
1991). It was already known to be the essential component of
the multi-protein sub-nuclear structures commonly referred to as
the PML-nuclear bodies (NBs) (Zhong et al., 1999), which con-
trol a variety of post-translational modifications (sumoylation,
phosphorylation, or acetylation) of a range of recruited partner
proteins (Figure 1) (Lallemand-Breitenbach and de The, 2010).
Unlike the well-established roles of PML and PML-NBs in solid
tumors and leukemia pathogenesis [which are effected through
modulation of the activity of p53 (Bernardi et al., 2004), Atk
(Trotman et al., 2006), mTOR, HIF1α (Bernardi et al., 2006), or
mitochondrial regulatory pathways (Giorgi et al., 2010)], little is
known about the role of this tumor suppressor in stem cell biology
or the mechanisms of its regulation of cancer metabolism.
PML IN STEM CELLS
The phosphoinositide 3-kinase (PI3-kinase) signaling pathway
controls cell proliferation, growth, and survival by integrating
numerous upstream signals, including growth factors, nutrients,
and oxygen status. Critical modulators and effectors of this path-
way, such as PTEN (phosphatase with tensin homology, which
is deleted on chromosome 10) and the forkhead O (FoxO) fam-
ily, have recently been implicated in the stem cell biology of the
hematopoietic system (Trotman et al., 2006; Yilmaz et al., 2006;
Zhang et al., 2006; Miyamoto et al., 2007; Tothova et al., 2007; Guo
et al., 2008; Ito et al., 2008), where improper Akt-mTorc1 signaling
can lead to profound defects in the maintenance of hematopoietic
stem cells (HSCs). Indeed, growing evidence suggests that tight
regulation of this signaling pathway is essential to the maintenance
of normal hematopoiesis.
Promyelocytic leukemia had previously been identified as a
negative regulator of Akt and mTOR pathway at multiple lev-
els. We recently defined a critical role for PML in the stem cells of
the hematopoietic system (Ito et al., 2008), and demonstrated that
deletion of Pml leads to loss of quiescence in HSCs, resulting in
their transient amplification and subsequent exhaustion.
We further defined a critical role for PML in the mainte-
nance of leukemia-initiating cells (LICs) in disease models of
chronic myeloid leukemia (CML),and presented a new therapeutic
approach based on targeting quiescent LICs by pharmacologi-
cal inhibition of PML. PML is often elevated in patients with
CML, and these higher levels have been shown to correlate with
poor clinical outcomes. In addition, Pml-deficient LICs become
exhausted with time, and are incapable of generating CML in
transplanted animals. Interestingly, inhibition of PML by arsenic
trioxide (As2O3) disrupted LIC maintenance and sensitized LICs
to anti-leukemic therapy with little adverse effect on normal HSCs
(Ito et al., 2008).
All these findings strongly support an essential role for PML
in LIC biology, and suggest there could be a window for effec-
tive CML therapy via PML-targeting. This in turn inspired us
to propose that PML-lowering drugs should be used temporar-
ily at leukemia onset, along with, or followed by, standard-of-
care regimens. However, questions remain regarding the molec-
ular mechanism underlying the effect of PML on HSC mainte-
nance.
A NEW ROLE FOR PML IN METABOLIC FUNCTION
Normal cells rely primarily on mitochondrial oxidative
phosphorylation to produce adenosine triphosphate (ATP), which
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FIGURE 1 | Multi-functional protein, PML. PML and/or PML-NBs
regulate a diverse of cellular functions, including senescence,
apoptosis, metabolism, stem cell function, and angiogenesis. These
functions are achieved by different biochemical means such as
post-translational modification, transcriptional regulation as well as
mitochondria function.
maintains cellular viability and functions by utilizing three major
bioenergetic fuels: glucose, glutamine, and fatty acids.
Many cancer cells, however, have been shown to rely on aer-
obic glycolysis for survival, growth, and the efficient production
of biomass [recent studies indicate that some cancer cells depend
on glutamine as well (Dang, 2010)]. This altered metabolism in
cancers is the result of either oncogene activation or the loss of
tumor suppressor genes in multiple signaling pathways, includ-
ing the PI3-kinase and Myc pathways (Deberardinis et al., 2008;
Vander Heiden et al., 2009; Dang, 2010). Relatively little is known,
however, about the role of fatty acids as a bioenergetic fuel in the
growth and survival of cancer cells.
It is established, however, that in breast cancer cells, fatty acid
oxidation (FAO) functions as the source of ATP once epithelial
glandular structures lose their normal architecture and cancer cells
start to proliferate aberrantly, migrating far from the extracellular
matrix and undergoing metabolic stress (Schafer et al., 2009). This
loss of attachment results in the inhibition of glucose uptake and
glycolytic influx, while the ensuing decrease in NADPH leads to
increased reactive oxygen species (ROS), which inhibits fatty acid
catabolism. Enhancing FAO by antioxidant treatment increases
the survival capacity of these cells upon loss of attachment.
As part of this developing picture of how breast cancer is fueled,
we have recently identified a tumoral metabolic reprograming for
PML that is central to breast cancer cell survival. As we have noted,
FAO is known to play an important role in the metabolic challenge
unleashed by loss of attachment in breast cancer cells (Carracedo
et al., 2012). We have shown that under these conditions, PML acts
as both a negative regulator of peroxisome proliferator-activated
receptor (PPAR) γ co-activator 1α (PGC1α) acetylation and an
activator of PPAR-FAO signaling. The PML-PPARδ-FAO pathway
in primary breast cancer cells grown in methylcellulose renders
these cells resistant to anoikis, which results in luminal filling
in a 3D basement membrane breast culture model (Carracedo
et al., 2012). Mechanistically, PML-NBs recruit SIRT1 deacetylase
to greatly decrease PGC1A acetylation, enhancing its co-activator
function on PPARδ signaling and triggering the expression of
enzymes which control FAO. PML is consistently enriched in
triple-negative cases, and PML expression in breast cancer cor-
relates with both activated PPAR signaling and reduced time to
recurrence, a gene signature of poor prognosis.
Taken together, these findings have clear therapeutic implica-
tions, suggesting that targeting PML may represent a novel thera-
peutic avenue in the treatment of triple-negative breast cancer. At
the same time, they raise the issue of whether a metabolic func-
tion of PML can be similarly described and targeted as a common
cellular mechanism in other tissue systems (e.g., hematopoiesis)
as well as in stem cell biology.
FATTY ACID METABOLISM AND HEMATOPOIETIC STEM CELL
HOMEOSTASIS
Under normal conditions, HSCs remain in a quiescent state and
respond to environmental insults by entering the cell cycle, divid-
ing, and giving rise to multi-potent progenitors (Lemischka and
Moore, 2003; Arai et al., 2004; Fuchs et al., 2004; Wilson and
Trumpp, 2006; Morrison and Spradling, 2008). Over the past few
years, the metabolism of these essentially quiescent cells has been
the focus of many studies (Gan et al., 2010; Gurumurthy et al.,
2010; Nakada et al., 2010; Simsek et al., 2010; Takubo et al., 2010;
Suda, 2011). The most recent studies have focused largely on gly-
colysis and energy homeostasis, however, while the contribution of
fatty acid metabolism to HSC maintenance has remained relatively
unexplored (Suda, 2011).
We modeled our investigation of these questions by first trans-
lating the known role that PML plays in breast cancer to a similar
possible role in stem cell biology. We then demonstrated that PML
activates PPARδ, a nuclear receptor that plays a key role in stem cell
maintenance. The fact that PPARδ levels and signaling output are
reduced during the differentiation of HSCs inspired us to further
elucidate the role of fatty acid metabolisms in HSC maintenance.
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In vivo and in vitro assays soon demonstrated that conditional
loss of Ppard profoundly affects quiescence, maintenance, and
function of HSCs, while treatment with PPARδ activators increases
HSC maintenance and function. Conversely, defects in Pml−/−
HSCs were partly rescued by PPARδ agonists. PPARs are central
regulators of metabolism and control mitochondrial function, in
particular FAO (Braissant et al., 1996; Michalik et al., 2006; Taka-
hashi et al., 2007). Pharmacological abrogation of FAO mimics the
consequence genetic loss of Pml, resulting in the ultimate loss of
HSC maintenance, and antagonizing the beneficial effects achieved
by PPAR agonists in terms of improving HSC function (Ito et al.,
2012).
Several essential pathways in HSC maintenance, including
FOXO-oxidative stress (Miyamoto et al., 2007; Yalcin et al., 2008),
hypoxia-glycolysis (Simsek et al., 2010; Takubo et al., 2010), the
LKB1-mTOR pathway (Gan et al., 2010; Gurumurthy et al., 2010;
Nakada et al., 2010), are clearly implicated in energy metabolism.
We now have direct evidence identifying fatty acid metabolism as
a critical factor in the self-renewal of HSCs.
PML-PPARδ PATHWAY AND FAO CONTROL HSC
ASYMMETRIC DIVISION
Stem cells have two specific functions; self-renewal and pluripo-
tency. One of the central tasks of stem cell biology is to understand
the modes and mechanisms that regulate self-renewal and com-
mitment of stem cells, as alterations in this equilibrium impact
hematopoietic homeostasis and maintenance. Identifying the fac-
tors regulating this process is of high biological and therapeutic
relevance.
Possible division patterns of stem cells include asymmetric divi-
sion, where an HSC gives rise to either two distinct daughter
cells, one HSC and one committed progenitor cell (an outcome
which results in HSC maintenance), or symmetric division, which
can result in either two HSCs (HSC expansion) or two commit-
ted progenitors (HSC exhaustion). Asymmetric cell division has
recently been suggested as a regulator of cell-fate decisions in the
mammalian hematopoietic system, with crucial roles in stem cell
renewal to ensure that a fraction of the daughter cells retains stem
cell features while replenishing the compartment (Suda et al., 1983,
1984; Lansdorp, 1997; Metcalf, 1998; Morrison and Kimble, 2006).
We studied the symmetry of cell divisions of HSCs using a
binary immunophenotypical assay that takes advantage of two
surface markers, Tie2 and CD48 (Arai et al., 2004; Kiel et al., 2005;
Ito et al., 2012). We found that in single cell culture assays, more
than 40% of purified HSC compartments asymmetrically divided,
giving rise after the first cell division to two distinct daughter cells,
Tie2posCD48neg (HSC) and Tie2negCD48pos (a committed cell).
This resulted in the discovery of a link between the regulation of
fatty acid metabolism by PML and control of HSC division (Ito
et al., 2012). Depletion of Ppard or Pml, as well as mitochondr-
ial FAO inhibition, results in a symmetric commitment of HSC
daughter cells in vitro and in vivo. On the other hand, pharma-
cological PPARδ activation increases asymmetric division, thereby
supporting the maintenance of the HSC population (Figure 2).
Importantly, each of the sequential key steps in this cascade of
fatty acid metabolism can be pharmacologically intervened: PML
by interferons and As2O3, PPARδ by existing agonists available for
human use, and FAO by specific inhibitors of the mitochondrial
enzymes responsible for fatty acid catabolism.
These findings strongly suggest that a metabolic requirement
exists for the exquisite regulation of asymmetric division of HSCs,
which sets the baseline for metabolic reprograming during the
process of stem cell differentiation. These evidences not only act as
bridge between nuclear organization, transcriptional control, and
lipid metabolism in decisions underlying asymmetric cell division,
but also have major implications for therapeutic manipulation of
HSCs.
CLINICAL IMPLICATION AND FUTURE DIRECTIONS
Our study has uncovered a role for the PML–PPAR-δ–FAO path-
way in the control of HSC asymmetric division and cell mainte-
nance; these findings may open new therapeutic avenues through
the manipulation of normal HSCs. For instance, the benefit of
PPARδ on HSC function implies the therapeutic potential of
FIGURE 2 | A model for regulation of asymmetric division by
PML-PPARδ-fatty acid oxidation. PML increases the fraction of
de-acetylated PGC1α, and leads to the activation of PPAR signaling and
fatty acid oxidation (FAO). These metabolic changes promote HSCs
toward the fate of asymmetric cell division, leading to their
maintenance.
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PPARδ activators, especially in conditions where stem cell function
needs to be maximized, as is the case with hematopoietic recovery
after bone marrow transplantation.
However, there are several issues with this approach still to be
discussed and elucidated in greater depth in future studies.
First, while the potential therapeutic power of pharmacolog-
ical inhibitors of FAO may lie in their ability to exhaust stem
cells, it remains to be determined whether PML exerts such a role
in leukemia stem cells (or LICs). We have previously shown that
A2O3, a PML-targeting compound, effectively induces quiescent
LICs to enter the cell cycle (Ito et al., 2008). The demonstrated fact
that Pml-deficient HSCs exhibit reduced PPAR signaling and FAO
tempts us to propose that the use of pharmacological inhibitors
of FAO to promote LIC exhaustion may represent an alterna-
tive therapeutic strategy to targeting differentiated leukemic cells
(Samudio et al., 2010). Further extensive investigations will con-
firm whether FAO inhibitors and/or a combination of these
drugs with compounds targeting the proliferating leukemic cell
pool will have the power to effectively contain or reverse this
disease.
Second, the fact that PML appears to be the upstream regulator
of this key regulatory cascade raises the issue of how PML and
PML-NBs are themselves regulated in stem cells. Third, these
metabolic requirements may parallel similar requirements in
other tissue stem cells (e.g., neural stem cells) as well as human
hematopoiesis. Lastly and perhaps most importantly, it is still
unknown how the metabolic changes induced by FAO can directly
control asymmetric HSC division. It will also be of interest to
determine how PML-PPAR-FAO pathways asymmetrically segre-
gate cellular organelles as well as cell-fate determinants. Specific
“druggable” targets with therapeutic value are likely to be deter-
mined by directly linking the mechanisms of cell metabolism and
stem cell division.
On the basis of what we have discussed, it is clear that PML is
a unique protein that regulates diverse cellular functions, and that
we now understand in greater detail the mechanisms it regulates,
knowledge which may soon be translated into effective treatment
modalities. Open questions remain, however, regarding PML and
its functions, that will no doubt motivate further investigation of
this intriguing tumor suppressor.
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